4.5 Article

EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1

期刊

JOURNAL OF CELL SCIENCE
卷 129, 期 13, 页码 2599-2612

出版社

COMPANY OF BIOLOGISTS LTD
DOI: 10.1242/jcs.185629

关键词

CFTR; cAMP; EPAC1; Membrane stability; Protein trafficking

资金

  1. Fundacao para a Ciencia e a Tecnologia [UID/MULTI/04046/2013, EXPL/BIM-MEC/1451/2013]
  2. European Respiratory Society (Romain Pauwels Research Award)
  3. British Heart Foundation [PG/15/5/31110, RG/12/3/29423]
  4. British Heart Foundation [RG/12/3/29423, PG/15/5/31110] Funding Source: researchfish
  5. Fundação para a Ciência e a Tecnologia [EXPL/BIM-MEC/1451/2013] Funding Source: FCT

向作者/读者索取更多资源

Cyclic AMP (cAMP) activates protein kinase A (PKA) but also the guanine nucleotide exchange factor 'exchange protein directly activated by cAMP' (EPAC1; also known as RAPGEF3). Although phosphorylation by PKA is known to regulate CFTR channel gating the protein defective in cystic fibrosis -the contribution of EPAC1 to CFTR regulation remains largely undefined. Here, we demonstrate that in human airway epithelial cells, cAMP signaling through EPAC1 promotes CFTR stabilization at the plasma membrane by attenuating its endocytosis, independently of PKA activation. EPAC1 and CFTR colocalize and interact through protein adaptor NHERF1 (also known as SLC9A3R1). This interaction is promoted by EPAC1 activation, triggering its translocation to the plasma membrane and binding to NHERF1. Our findings identify a new CFTR-interacting protein and demonstrate that cAMP activates CFTR through two different but complementary pathways\-the well-known PKA-dependent channel gating pathway and a new mechanism regulating endocytosis that involves EPAC1. The latter might constitute a novel therapeutic target for treatment of cystic fibrosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据